Literature DB >> 21896150

Angiotensin receptor blockers: pharmacology, efficacy, and safety.

Addison A Taylor1, Helmy Siragy, Shawna Nesbitt.   

Abstract

KEY POINTS AND PRACTICAL RECOMMENDATIONS: •  The angiotensin receptor blockers are highly effective antihypertensive agents that are also particularly well tolerated. •  There are no major differences in efficacy or other clinical characteristics among older drugs in this class, although some of the newer agents may more effectively reduce blood pressure than older agents. •  Major randomized clinical trials have demonstrated that angiotensin receptor blockers provide significant outcomes benefits in conditions such as diabetic nephropathy, chronic heart failure or heart failure following myocardial infarction, hypertension with left ventricular hypertrophy and in patients whose histories of previous events or complicated diabetes puts them at high cardiovascular risk. •  In treating hypertension, angiotensin receptor blockers can be used as first-line therapy or added at later stages of treatment titration. •  These drugs are very effective in combination with thiazide diuretics or calcium channel blockers and there are several single-pill, fixed-dose combinations of angiotensin receptor blockers with hydrochlorothiazide, amlodipine, or aliskiren. These combinations can be given as initial therapy (where appropriate) or later in the course of treatment. Three-drug combinations (angiotensin receptor blocker plus amlodipine plus hydrochlorothiazide and angiotensin receptor blocker plus aliskiren plus hydrochlorothiazide) are also available.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896150      PMCID: PMC8108884          DOI: 10.1111/j.1751-7176.2011.00518.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  76 in total

1.  Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.

Authors:  William B White; Michael A Weber; Domenic Sica; George L Bakris; Alfonso Perez; Charlie Cao; Stuart Kupfer
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

2.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

3.  Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke.

Authors:  Koji Yamada; Toshikazu Hirayama; Yasuhiro Hasegawa
Journal:  J Stroke Cerebrovasc Dis       Date:  2007 Sep-Oct       Impact factor: 2.136

4.  Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.

Authors:  Suzanne Oparil; Michael Melino; James Lee; Victor Fernandez; Reinilde Heyrman
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Authors:  Kenneth Jamerson; Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Victor Shi; Allen Hester; Jitendra Gupte; Marjorie Gatlin; Eric J Velazquez
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

Review 7.  Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.

Authors:  Balraj S Heran; Michelle My Wong; Inderjit K Heran; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

8.  Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.

Authors:  Sverre E Kjeldsen; Gordon T McInnes; Giuseppe Mancia; Tsushung A Hua; Stevo Julius; Michael A Weber; Antonio Coca; Xavier Girerd; Kenneth Jamerson; Pierre Larochelle; Thomas Macdonald; Roland E Schmieder; M Anthony Schork; Reuven Viskoper; Jiri Widimsky; Alberto Zanchetti
Journal:  Blood Press       Date:  2008       Impact factor: 2.835

9.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.

Authors:  Roland E Schmieder; Sverre E Kjeldsen; Stevo Julius; Gordon T McInnes; Alberto Zanchetti; Tsushung A Hua
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

10.  The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.

Authors:  George L Bakris; Domenic Sica; Michael Weber; William B White; Andrew Roberts; Alfonso Perez; Charlie Cao; Stuart Kupfer
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-02       Impact factor: 3.738

View more
  22 in total

Review 1.  Fimasartan: A New Angiotensin Receptor Blocker.

Authors:  Hae-Young Lee; Byung-Hee Oh
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

2.  Does outcome reporting bias "cause" cancer? Risks associated with hidden data on Angiotensin receptor blockers.

Authors:  Gregory Egan; Jana Lee; Rajwant Minhas; Aaron M Tejani
Journal:  Can J Hosp Pharm       Date:  2012-09

Review 3.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

4.  A compendium of antihypertensive therapy.

Authors:  Keith C Ferdinand
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-27       Impact factor: 3.738

5.  Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers might be associated with lung adenocarcinoma risk: a nationwide population-based nested case-control study.

Authors:  Han-Lin Hsu; Chih-Hsin Lee; Chien-Hsin Chen; Jun-Fu Zhan; Szu-Yuan Wu
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 6.  The effect of angiotensin II receptor blockers on hyperuricemia.

Authors:  Marissa L Wolff; Jennifer L Cruz; Adam J Vanderman; Jamie N Brown
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

7.  Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.

Authors:  Joseph J Saseen; Vahram Ghushchyan; Shuchita Kaila; Richard R Allen; Kavita V Nair
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-09-19       Impact factor: 3.738

8.  Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements.

Authors:  Alfonso Perez; Charlie Cao
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-15       Impact factor: 3.738

9.  The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.

Authors:  Alfonso Perez; Charlie Cao
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-25       Impact factor: 3.738

10.  The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.

Authors:  Raj Padwal; Mu Lin; Dean T Eurich
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-08-19       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.